In its classic hormonal role, erythropoietin (EPO) is produced by the kidney and regulates
the number of erythrocytes within the circulation to provide adequate tissue oxygenation …

Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood
cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor …

Diabetic cardiomyopathy is a diabetic complication due to oxidative stress injuries. This
study examined the protecting influence of thymoquinone (TQ) on diabetes‐caused cardiac …

Erythropoietin (EPO) may become a potential therapeutic candidate for the treatment of the
neurodegenerative disorder—Parkinson's disease (PD), since EPO has been found to …

During normal aging, the heart undergoes functional, morphological and cellular changes.
Although aging per se does not lead to the expression of heart failure, it is likely that age …

ABSTRACT Introduction Erythropoiesis-stimulating agents (ESAs) are the standard of
treatment for anemia in chronic kidney disease. Hypoxia-inducible factor prolyl hydroxylase …

Aims We intended to delineate the mechanisms of erythropoietin (EPO)-induced cardiac
vascular endothelial growth factor (VEGF) production and to establish if VEGF is crucial for …

Background—Endogenous erythropoietin is increased in patients with heart failure (HF).
Previous small-scale data suggest that these erythropoietin levels are related to prognosis …

Monocytes play an important role in immune defence, inflammation, and tissue remodelling.
Nevertheless, the role of monocytes in cardiovascular disease is obscure. Indeed …

Background Recent studies revealed that erythropoietin (EPO) has tissue-protective effects
in the heart by increasing vascular endothelial growth factor (VEGF) expression and …